Modified Bortezomib-based Combination Therapy for Multiple Myeloma

Inclusion Criteria: * Diagnosis of multiple myeloma based on standard diagnosis criteria: * plasmacytomas on tissue biopsy * bone marrow plasmacytosis * monoclonal immunoglobulin spike on serum electrophoresis * lytic bone lesions. * Must have relapsed or relapsed/refractory disease * 18 years of age or older * All baseline studies must be performed within 21 days of enrollment. * ECOG performance status of 0 to 2 Exclusion Criteria: * Renal insufficiency (serum creatinine levels \> 2mg/dL) * Concomitant therapy medications that include corticosteroids * Peripheral neuropathy of Grade 3 or greater or painful Grade 2 * Evidence of mucosal or internal bleeding and/or platelet refractory * ANC \< 1000 cells/mm3 * Hemoglobin \< 8.0 g/dL * AST (SGOT and ALT) \> 2 x ULN * Intolerance to bortezomib or CC-5013 in the past or significant allergy to either compound, boron or mannitol * Known hypersensitivity to thalidomide or the development of erythema nodosum * Active infection or serious co-morbid medical condition * Pregnant or breast-feeding women * Prior malignancy with the last three years except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, in situ breast cancer, on in-situ prostate cancer